Compare Nxera Pharma Co., Ltd. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 1.54%
- The company has been able to generate a Return on Equity (avg) of 1.54% signifying low profitability per unit of shareholders funds
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.07
3
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 1.54%
4
Flat results in Jun 26
5
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
JPY 85,158 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.64
-15.67%
1.34
Revenue and Profits:
Net Sales:
7,654 Million
(Quarterly Results - Jun 2026)
Net Profit:
-202 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.65%
0%
-20.65%
6 Months
4.28%
0%
4.28%
1 Year
4.87%
0%
4.87%
2 Years
-37.89%
0%
-37.89%
3 Years
-46.23%
0%
-46.23%
4 Years
-41.54%
0%
-41.54%
5 Years
-41.72%
0%
-41.72%
Nxera Pharma Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
30.96%
EBIT Growth (5y)
-281.01%
EBIT to Interest (avg)
-1.16
Debt to EBITDA (avg)
6.40
Net Debt to Equity (avg)
0.43
Sales to Capital Employed (avg)
0.21
Tax Ratio
2.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.44%
ROE (avg)
1.54%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.41
EV to EBIT
-57.94
EV to EBITDA
61.29
EV to Capital Employed
1.25
EV to Sales
3.82
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2.15%
ROE (Latest)
-15.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
7,654.00
8,450.00
-9.42%
Operating Profit (PBDIT) excl Other Income
231.00
156.00
48.08%
Interest
485.00
1,258.00
-61.45%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-202.00
-2,377.00
91.50%
Operating Profit Margin (Excl OI)
-112.90%
-111.10%
-0.18%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -9.42% vs 4.21% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 91.50% vs -67.16% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
29,615.00
28,835.00
2.71%
Operating Profit (PBDIT) excl Other Income
-3,710.00
-1,380.00
-168.84%
Interest
859.00
777.00
10.55%
Exceptional Items
-1,994.00
-1,209.00
-64.93%
Consolidate Net Profit
-12,530.00
-4,838.00
-158.99%
Operating Profit Margin (Excl OI)
-272.70%
-186.00%
-8.67%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 2.71% vs 125.87% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -158.99% vs 32.74% in Dec 2024
About Nxera Pharma Co., Ltd. 
Nxera Pharma Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






